Passage Bio Inc [PASG] stock is trading at $10.89, up 8.74%. An important factor to consider is whether the stock is rising or falling in short-term value. The PASG shares have gain 20.87% over the last week, with a monthly amount glided 27.22%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Rodman & Renshaw started tracking the stock with Buy rating on September 03, 2024, and set its price target to $7. On March 08, 2022, downgrade downgraded it’s rating to Neutral. Goldman downgraded its rating to a Neutral and decreased its price target to $6 on January 19, 2022. Raymond James initiated its recommendation with an Outperform and recommended $29 as its price target on July 01, 2021. BTIG Research started tracking with a Buy rating for this stock on June 15, 2021, and assigned it a price target of $25. In a note dated March 04, 2021, Goldman upgraded a Buy rating on this stock and boosted its target price from $28 to $30.
Passage Bio Inc [PASG] stock has fluctuated between $5.12 and $20.20 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Passage Bio Inc [NASDAQ: PASG] shares were valued at $10.89 at the most recent close of the market. An investor can expect a potential drop of -44.9% based on the average PASG price forecast.
Analyzing the PASG fundamentals
Gross Profit Margin for this corporation currently stands at 0.13% with Operating Profit Margin at -19.23%, Pretax Profit Margin comes in at -17.7%, and Net Profit Margin reading is -17.7%. To continue investigating profitability, this company’s Return on Assets is posted at -0.72, Equity is -1.04 and Total Capital is -1.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.65.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.97 points at the first support level, and at 9.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.56, and for the 2nd resistance point, it is at 12.24.
Ratios To Look Out For
For context, Passage Bio Inc’s Current Ratio is 2.51. On the other hand, the Quick Ratio is 2.51, and the Cash Ratio is 2.91.
Transactions by insiders
Recent insider trading involved Lynx1 Capital Management LP, 10% Owner, that happened on Sep 12 ’25 when 19783.0 shares were purchased. 10% Owner, Lynx1 Capital Management LP completed a deal on Sep 15 ’25 to buy 11900.0 shares. Meanwhile, 10% Owner Lynx1 Capital Management LP bought 325.0 shares on Sep 11 ’25.
